0001171843-20-007223.txt : 20201026 0001171843-20-007223.hdr.sgml : 20201026 20201026074849 ACCESSION NUMBER: 0001171843-20-007223 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20201026 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20201026 DATE AS OF CHANGE: 20201026 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc. CENTRAL INDEX KEY: 0001629137 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274825712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37539 FILM NUMBER: 201259081 BUSINESS ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650741-7700 MAIL ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 8-K 1 f8k_102620.htm FORM 8-K Form 8-K
0001629137 False 0001629137 2020-10-26 2020-10-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  October 26, 2020

_______________________________

Global Blood Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware001-3753927-4825712
(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

181 Oyster Point Blvd.

South San Francisco, California 94080

(Address of Principal Executive Offices) (Zip Code)

(650) 741-7700

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per shareGBTThe NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company,indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 
 
Item 8.01. Other Events.

On October 26, 2020, Global Blood Therapeutics, Inc. issued a press release titled "GBT Presents Data at 15th Annual Scientific Conference on Sickle Cell and Thalassemia." A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.Description
  
99.1Press Release, dated October 26, 2020
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 Global Blood Therapeutics, Inc.
   
  
Date: October 26, 2020By: /s/ Jeffrey Farrow        
  Jeffrey Farrow
  Chief Financial Officer
(Principal Financial Officer)
  

 

 EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

EXHIBIT 99.1

GBT Presents Data at 15th Annual Scientific Conference on Sickle Cell and Thalassemia

Real-world effectiveness data on Oxbryta® (voxelotor) in the treatment of sickle cell disease featured as oral presentation

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), today announced its participation in the 15th Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) and 1st EHA European Sickle Cell Conference, taking place online on Oct. 26-31, 2020. Two abstracts have been accepted for presentation, including real-world effectiveness data of Oxbryta® (voxelotor) tablets in the treatment of sickle cell disease (SCD).

“GBT is focused on addressing sickle cell disease at its root cause to seek to modify the course of the disease, and, ultimately, mitigate the serious and life-threatening complications that often lead to long-term damage and early death,” said Ted W. Love, M.D., president and CEO of GBT. “We’re pleased to be at ASCAT 2020, where we are sharing real-world effectiveness data demonstrating that the benefits of treatment of sickle cell patients with Oxbryta were consistent with the results of our Phase 3 HOPE Study.”

The two abstracts presented at the conference provide greater insight into the safety and efficacy of Oxbryta:

  • A retrospective chart review study to assess the real-world effectiveness of voxelotor based on data during the first several months post-U.S. FDA approval. In a sample of charts from 56 patients with SCD, voxelotor increased hemoglobin by more than 1 g/dL on average and decreased hemolysis markers to a degree consistent with the randomized controlled HOPE trial results. Evidence also suggests that voxelotor treatment was associated with improvement in important symptoms of SCD, such as pain and fatigue, and other aspects of quality of life.

  • The case report of a patient with SCD treated with voxelotor after presenting with a significant drop in hemoglobin, who was not responsive to transfusion with red blood cells in association with hospitalization for COVID-19. In this case, the patient's hemoglobin and overall clinical status improved rapidly with voxelotor treatment, thereby avoiding exchange transfusion, sparing red blood cell units and decreasing exposure of health care providers to COVID-19, all of which are important considerations during this era of pandemic and limited blood supply.

Details of the ASCAT presentations are as follows:

Wednesday, Oct. 28
Abstract Session: New Therapies
Real-World Effectiveness of Voxelotor for the Treatment of Sickle Cell Disease: A Chart Review Study
Presenter: Kenneth Bridges, M.D., GBT
Time: 11 a.m. GMT

Virtual Presentation in Poster Room
Sickle Cell Anemia and COVID-19: Use of Voxelotor to Avoid Transfusion
Presenter: William B. Ershler, M.D., Inova Schar Cancer Institute

As part of its presence at ASCAT, GBT will host an educational online symposium, “Getting to the Root Cause: Understanding the Devastating Impact of SCD on Patients,” on Monday, Oct. 26, 7-8 p.m. GMT. The symposium will include presentations by Caterina Minniti, M.D., professor of clinical medicine and pediatrics at Einstein College of Medicine and director of the Sickle Cell Center for Adults at Montefiore Medical Center; and Bart Biemond, M.D., Ph.D., professor of internal medicine and hematologist at the Faculty of Medicine of the University of Amsterdam. More information about the symposium, which is available to registered attendees of the ASCAT meeting, can be found in the conference program.

Coinciding with ASCAT, today GBT released a comprehensive report, “Overview of the Sickle Cell Disease Environment in Select European Countries,” in order to help raise awareness of SCD in Europe. The report is based on research conducted in five European countries and explores the burden of the disease on patients, families and health care systems. In addition, the report examines existing public policy efforts to address and alleviate the challenges faced by those living with SCD. SCD is one of the most prevalent genetic rare diseases in Europe, and despite a clinical understanding of SCD, estimated life expectancy for those affected by the disease is significantly lower than the European average, indicating an urgent need to improve the quality of care for these patients.

About Sickle Cell Disease
Sickle cell disease (SCD) affects an estimated 100,000 people in the United States,1 an estimated 52,000 people in Europe2 and millions of people throughout the world, particularly among those whose ancestors are from sub-Saharan Africa.1 It also affects people of Hispanic, South Asian, Southern European and Middle Eastern ancestry.1 SCD is a lifelong inherited rare blood disorder that impacts hemoglobin, a protein carried by red blood cells that delivers oxygen to tissues and organs throughout the body.3 Due to a genetic mutation, individuals with SCD form abnormal hemoglobin known as sickle hemoglobin. Through a process called hemoglobin polymerization, red blood cells become sickled – deoxygenated, crescent-shaped, and rigid.3-5 The sickling process causes hemolytic anemia (low hemoglobin due to red blood cell destruction) and blockages in capillaries and small blood vessels, which impede the flow of blood and oxygen throughout the body. The diminished oxygen delivery to tissues and organs can lead to life-threatening complications, including stroke and irreversible organ damage.4-7

About Oxbryta® (voxelotor) Tablets
Oxbryta (voxelotor) is an oral, once-daily therapy for patients with sickle cell disease (SCD). Oxbryta works by increasing hemoglobin’s affinity for oxygen. Since oxygenated sickle hemoglobin does not polymerize, GBT believes Oxbryta blocks polymerization and the resultant sickling and destruction of red blood cells, which are primary pathologies faced by every single person living with SCD. With the potential to improve hemolytic anemia and oxygen delivery, GBT believes that Oxbryta has the potential to modify the course of SCD. On Nov. 25, 2019, Oxbryta received U.S. Food and Drug Administration (FDA) accelerated approval for the treatment of SCD in adults and children 12 years of age and older.8 As a condition of accelerated approval, GBT will continue to study Oxbryta in the HOPE-KIDS 2 Study, a post-approval confirmatory study using transcranial Doppler (TCD) flow velocity to assess the ability of the therapy to decrease stroke risk in children 2 to 15 years of age.

In recognition of the critical need for new SCD treatments, the FDA granted Oxbryta Breakthrough Therapy, Fast Track, Orphan Drug and Rare Pediatric Disease designations for the treatment of patients with SCD. Additionally, Oxbryta has been granted Priority Medicines (PRIME) designation from the European Medicines Agency (EMA), and the European Commission (EC) has designated Oxbryta as an orphan medicinal product for the treatment of patients with SCD.

GBT plans to seek regulatory approvals to expand the potential use of Oxbryta in the United States for the treatment of SCD in children age 4 to 11 years and to treat hemolytic anemia in SCD in people age 12 years and older in Europe.

Important Safety Information
Oxbryta should not be taken if the patient has had an allergic reaction to voxelotor or any of the ingredients in Oxbryta. See the end of the patient leaflet for a list of the ingredients in Oxbryta. Oxbryta can cause serious side effects, including serious allergic reactions. Patients should tell their health care provider or get emergency medical help right away if they get rash, hives, shortness of breath or swelling of the face.

Patients receiving exchange transfusions should talk to their health care provider about possible difficulties with the interpretation of certain blood tests when taking Oxbryta.

The most common side effects of Oxbryta include headache, diarrhea, stomach (abdominal) pain, nausea, tiredness, rash and fever. These are not all the possible side effects of Oxbryta. Before taking Oxbryta, patients should tell their health care provider about all medical conditions, including if they have liver problems; if they are pregnant or plan to become pregnant as it is not known if Oxbryta can harm an unborn baby; or if they are breastfeeding or plan to breastfeed as it is not known if Oxbryta can pass into breastmilk or if it can harm a baby. Patients should not breastfeed during treatment with Oxbryta and for at least two weeks after the last dose.

Patients should tell their health care provider about all the medicines they take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Some medicines may affect how Oxbryta works. Oxbryta may also affect how other medicines work.

Patients are advised to call their doctor for medical advice about side effects. Side effects can be reported to the FDA at 1-800-FDA-1088. Side effects can also be reported to Global Blood Therapeutics at 1-833-428-4968 (1-833-GBT-4YOU).

Full Prescribing Information for Oxbryta is available at Oxbryta.com.

About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor), the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a p-selectin inhibitor in development to address pain crises associated with the disease. In addition, GBT’s drug discovery teams are working on new targets to develop the next generation of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.

Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including statements containing the words “will,” “anticipates,” “plans,” “believes,” “forecast,” “estimates,” “expects,” and “intends,” or similar expressions. These forward-looking statements are based on GBT’s current expectations and actual results could differ materially. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. GBT intends these forward-looking statements, including statements regarding GBT’s priorities, dedication, focus, goals and vision; the safety, efficacy and mechanism of action of Oxbryta and other product characteristics; the commercialization, delivery, availability, use, and commercial and medical potential of Oxbryta; ongoing and planned studies of Oxbryta and related protocols, activities and expectations; the potential expansion of the approved use of Oxbryta for more patients in the U.S., and potential regulatory approval for Oxbryta to treat patients in Europe; raising awareness of SCD in Europe; altering the treatment, course and care of SCD and mitigating related complications; need to improve the quality of care for SCD patients in Europe; the potential of inclacumab; and advancing GBT’s pipeline, working on new targets and discovering, developing and delivering treatments, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and GBT makes this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect GBT’s current views about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to the company and on assumptions the company has made. GBT can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved, and, furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond GBT’s control including, without limitation, risks and uncertainties relating to the COVID-19 pandemic, including the extent and duration of the impact on GBT’s business, including commercialization activities, regulatory efforts, research and development, corporate development activities and operating results, which will depend on future developments that are highly uncertain and cannot be accurately predicted, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the U.S. and in other countries, and the effectiveness of actions taken globally to contain and treat the disease; the risks that GBT has only recently established its commercialization capabilities and may not be able to successfully commercialize Oxbryta; risks associated with GBT’s dependence on third parties for development, manufacture and commercialization activities related to Oxbryta; government and third-party payor actions, including those relating to reimbursement and pricing; risks and uncertainties relating to competitive products and other changes that may limit demand for Oxbryta; the risks regulatory authorities may require additional studies or data to support continued commercialization of Oxbryta; the risks that drug-related adverse events may be observed during commercialization or clinical development; data and results may not meet regulatory requirements or otherwise be sufficient for further development, regulatory review or approval; compliance with the funding and other obligations under the Pharmakon loan; and the timing and progress of GBT’s and Syros’ research and development activities under their collaboration; along with those risks set forth in GBT’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, and in GBT’s most recent Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission, as well as discussions of potential risks, uncertainties and other important factors in GBT’s subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, GBT assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

References

  1. Centers for Disease Control and Prevention website. Sickle Cell Disease (SCD). https://www.cdc.gov/ncbddd/sicklecell/data.html. Accessed June 3, 2019.
  2. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3182125. Accessed June 12, 2020.
  3. National Heart, Lung, and Blood Institute website. Sickle Cell Disease. https://www.nhlbi.nih.gov/health-topics/sickle-cell-disease. Accessed August 5, 2019.
  4. Rees DC, et al. Lancet. 2010;376(9757):2018-2031.
  5. Kato GJ, et al. Nat Rev Dis Primers. 2018;4:18010.
  6. Kato GJ, et al. J Clin Invest. 2017;127(3):750-760. 
  7. Caboot JB, et al. Paediatr Respir Rev. 2014;15(1):17-23.
  8. Oxbryta (voxelotor) tablets prescribing information. South San Francisco, Calif. Global Blood Therapeutics, Inc.; November 2019.

Contact:
Steven Immergut
GBT
650-410-3258
media@gbt.com

 EX-101.SCH 3 gnw-20190101.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gnw-20190101_def.xml XBRL DEFINITION FILE EX-101.LAB 5 gnw-20190101_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Class A [Member] Preferred Class A [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gnw-20190101_pre.xml XBRL PRESENTATION FILE XML 7 f8k_102620_htm.xml IDEA: XBRL DOCUMENT 0001629137 2020-10-26 2020-10-26 iso4217:USD shares iso4217:USD shares 0001629137 false 8-K 2020-10-26 Global Blood Therapeutics, Inc. DE 001-37539 27-4825712 181 Oyster Point Blvd. South San Francisco CA 94080 650 741-7700 false false false false Common Stock, par value $0.001 per share GBT NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover
Oct. 26, 2020
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 26, 2020
Entity File Number 001-37539
Entity Registrant Name Global Blood Therapeutics, Inc.
Entity Central Index Key 0001629137
Entity Tax Identification Number 27-4825712
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 181 Oyster Point Blvd.
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code 650
Local Phone Number 741-7700
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol GBT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

-8?20$3;8T.P6BP^0"X99K>] M9!:G%C:^? MVZH:TE[VE-S9NMQ=%A?BTX'HE'QY%V)N:I%FGJ:QJ,';>$<-!)U4Q-Z*0CZF ML6&P9:P!Q+MTFF6SU%L,9KD8M;:X1+_)UW,#ECQ ,ZE._< M]'<')O$8T.,5RMQD)HDU75Z(\4I!K-L53,[E9C(,]L""Q1]ZUYG\M(?8,V(/ M'U:-Y&:6J6"%'*7?Z/6M>CR#+@^H%7I")\!K*_#,U#88CIV,IDAO8O0]C.=0 MXIS_4R-5%1:PIJ+U$&3HD<%U!D.LL8DF"=9#;E9T!N[RZ .;O\P>=0>6N=6RKV'5[+E&''\GN4/ M4$L#!!0 ( !@^6E$D'INBK0 /@! : >&PO7W)E;',O=V]R:V)O M;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% M 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF& M!KS2O6H0DBBZ0=@S9)[NF:*'3^ 5!+ P04 " 8/EI199!YDAD! #/ P $P %M#;VYT96YT7U1Y M<&5S72YX;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[: M2J 2%85-K'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)* MM9-;$/?+Y8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!-FI6.5Z*U .EK M>MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ M!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO. M\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0 ( !@^6E$'04UB@0 +$ M 0 " 0 !D;V-0&UL4$L! A0#% M @ &#Y:40JMEQ_O *P( !$ ( !KP &1O8U!R;W!S M+V-O&UL4$L! A0#% @ &#Y:49E&PO=V]R:W-H965T&UL4$L! A0#% @ &#Y:4?WZORK. 0 @ 4 T M ( !<0P 'AL+W-T>6QE&PO=V]R:V)O M;VLN>&UL4$L! A0#% @ &#Y:420>FZ*M ^ $ !H M ( !LQ 'AL+U]R96QS+W=O9(9 0 SP, !, ( !F!$ %M#;VYT96YT7U1Y ><&5S72YX;6Q02P4& D "0 ^ @ XA( end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_102620.htm exh_991.htm gnw-20190101.xsd gnw-20190101_def.xml gnw-20190101_lab.xml gnw-20190101_pre.xml http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f8k_102620.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "gnw-20190101_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "f8k_102620.htm" ] }, "labelLink": { "local": [ "gnw-20190101_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "gnw-20190101_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "gnw-20190101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 63, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "gnw", "nsuri": "http://globenewswire.com/20190101", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_102620.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://globenewswire.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_102620.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The start date of the period covered in the document, in CCYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r9" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredClassAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Preferred Class A [Member]" } } }, "localname": "PreferredClassAMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r11": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r12": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r13": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r14": { "Name": "Forms 20-F, 40-F", "Number": "249", "Publisher": "SEC", "Section": "220 and 240", "Subsection": "f" }, "r15": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r18": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" } }, "version": "2.1" } ZIP 15 0001171843-20-007223-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-20-007223-xbrl.zip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